Recent clinical development of dendritic cell-based immunotherapy for prostate cancer.
Dendritic cells (DCs) are the most powerful immune cells that present antigens to T cells, resulting in a T cell response. Therapeutic strategies involving DCs have been explored in many malignancies, including prostate cancer. These strategies are designed to stimulate DC proliferation, promote antigen uptake and processing by DCs, or to directly provide antigen-loaded DCs. All approaches are designed to stimulate an antitumour T cell response leading to clinical benefit. Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Clinical effect has also been observed, prompting larger definitive trials.
Rini
Brian
B
UCSF Comprehensive Cancer Center, 1600 Divisidero, 3rd floor, San Francisco, CA 94115, USA. brini@medicine.ucsf.edu
D000230:Adenocarcinoma / Q000628:therapy*; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D008297:Male; D008565:Membrane Proteins / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D017430:Prostate-Specific Antigen / Q000235:genetics; D011471:Prostatic Neoplasms / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014162:Transfection; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D008565:Membrane Proteins; D012333:RNA, Messenger; C084881:flt3 ligand protein; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017430:Prostate-Specific Antigen